Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses.
Cost Offset Analysis of Interferon Beta Disease Modifying Therapies In Relapsing-Remitting Multiple Sclerosis.
Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment.
The crystal structure of an integral membrane fatty acid α-hydroxylase.
The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.
Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis.
Progressive cerebral atrophy in neuromyelitis optica.
Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer's Disease.
New pharmacological approaches against chronic bowel and bladder problems in paralytics.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Are Polyphenols Strong Dietary Agents Against Neurotoxicity and Neurodegeneration?
Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and Sjögren syndrome.
Transplantation of mesenchymal stem cells in a laryngeal carcinoma patient with radiation myelitis.
Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
Microglia in normal appearing white matter of multiple sclerosis are alerted but immunosuppressed.
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis.
Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes.
Efficacy of Schwann Cell (SC) transplantation for spinal cord repair is improved with combinatorial strategies.
Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Con.]
Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis.
Antiphospholipid antibodies: paradigm in transition.
Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms.
Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.

Pages